Subscription Center
Oct 7, 2008 07:54 AM | 1
Open access pioneer BioMed Central has been acquired by Springer, ScientificAmerican.com has learned.
Open access is the movement, recently bolstered by Congress, to make studies available for free online, instead of charging taxpayers who funded the research (and others) to read them. Many prominent scientists have backed it, signing on with BioMed Central and a non-profit open access publisher, the Public Library of Science.
BioMed Central publisher Matthew Cockerill announced the news in an email today to editors of BMC's journals.
Those in the open access movement had watched BioMed Central with keen interest. Founded in 2000, it was the first for-profit open access publisher and advocates feared that when the company was sold, its approach might change. But Cockerill assured editors that a BMC board of trustees "will continue to safeguard BioMed Central's open access policy in the future." Springer "has been notable...for its willingness to experiment with open access publishing," Cockerill said in a release circulated with the email to editors.
Read more about Science 2.0, which takes open access even further, with scientists publishing raw experimental results, here, and about an open access milestone in physics, here.
Tags:
biomed central,
open access,
springer,
biomedcentral
More News Blog:
Next: Chalfie, Shimomura and Tsien win Chemistry Nobel for lighting up cells
Previous: Work on broken symmetry garners Physics Nobel
See what we're tweeting about
BoraZ RT @Protohedgehog: And the #Scitable launch is go! Here's mine and @JLizRob's debut post: How do planets evolve? http://t.co/KXQqIW3bdf
FlyingTrilobite "Natural" fallacies and environmentalism on @ScienceBasedMed http://t.co/rTS7J7lzDg
sciamblogs RT @notscientific: .@Scitable launches ten new blogs and one new forum http://t.co/9kD5ZVBk78 #scitable
Deadline: Aug 31 2013
Reward: $100,000 USD
The Geoffrey Beene Foundation Alzheimer’s Initiative (GBFAI) is launching the 2013 Geoffrey Beene Global NeuroDiscovery Challenge whose
Deadline: Jul 30 2013
Reward: $100,000 USD
The Seeker desires a method for producing pseudoephedrine products in such a way that it will be extremely difficult for clandestine che
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
1 Comments
Add CommentThis is an important turn of events in the open access movement. I'm just learning about it recently, but it will revolutionize the way we access information and knowledge. Unlike other not-for-profit open access entities such as the Public Library of Science, Biomed Central is a for-profit open access entity. I hope that it will be able to maintain its true open access model and still turn a profit, which is its mission, under the ownership of Springer.
Reply | Report Abuse | Link to thisM.B.
NYC